Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab for prevention of migraine in Chinese adults
CTR20220109Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of fremanezumab in migraine, sponsored by Teva Pharmaceutical Industries Ltd.. Started Feb 2022; status: completed.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on CTR20220109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220109.